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34722
Nail-patella syndrome: An early dermatologic diagnosis
Sandra Oska, Henry Ford Health System, Department of Dermatology;
Kelly Kennelly, MS, Children’s Hospital of Michigan, Department of
Pediatrics, Division of Genetic, Genomic & Metabolic Disorders; Vinod
Misra, MD PhD, Children’s Hospital of Michigan, Department of Pediatrics,
Division of Genetic, Genomic & Metabolic Disorders
Presentation: A 3-month-old female presented with congenital onychodystrophy of
both upper extremities and unilateral postaxial polydactyly of her left lower
extremity. Physical examination was remarkable for dorsal pterygium of both first
fingers, triangular lunulae of the 2nd through 5th fingernails, and Type I postaxial
polydactyly of 5th digit without evidence of synonychia. Nail-patella syndrome
(NPS) was suspected.
Course and therapy: At presentation, radiographs did not show evidence of
hypoplastic patellae, elbow abnormalities, or iliac horns. Repeat imaging at 7
months of age suggested the presence of bilateral posterior iliac horns. Based on
clinical suspicion, molecular genetic testing was sent. A heterozygous pathogenic
variant in LMX1B (c.736C[T (p.Arg246*) was found, confirming a diagnosis of NPS.
Discussion: NPS is a clinically variable disorder associated with congenital
onychodystrophy, skeletal abnormalities including patellar aplasia or hypoplasia,
elbow abnormalities, and pathognomonic iliac horns. Early identifications of NPS is
important since almost half of affected individuals develop renal abnormalities
including proteinuria, hematuria, nephrotic syndrome, that may progress to endstage renal disease. Patient may also develop primary open-angle glaucoma and
ocular hypertension at an early age. The nail changes, including the presence of the
triangular lunulae, are among the earliest and most characteristic findings. This case
highlights the role of dermatologists in recognizing these early clinical features to
facilitate early multidisciplinary care.
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New clinical methodology directed for lesion count in patients
with truncal acne
Loan Towersey, Hopital Municipal Carlos Tortely
New clinical methodology directed for lesion count in patients with truncal acne.
Acne is a skin condition of the pilosebaceous unit that affects mainly the face, chest
and trunk. Most studies focus on facial acne. Few papers specifically address truncal
acne. Nevertheless, approximately 50% patients with facial acne also have acne of
the trunk, and all truncal areas may be affected. The study objective was to evaluate a
new methodology to evaluate lesion count in truncal acne. Using as reference the
methodology of lesion count developed by Lucky3 for facial acne, an individual
repositioning mask was used to count acne lesions on the chest and back, including
noninflammatory and inflammatory lesions. A transparent film paper was positioned on the upper back. Using a ballpoint pen, the dermatologist delineated the
area between shoulders and scapula tip where lesion counting was to be performed.
On the chest, the same procedure was implemented delineating the area between
clavicle and xyphoid. Suitability of the repositioning mask technique was confirmed
in a single center, open label, nonrandomized study in 51 subjects with a mean age of
23 years (min 13; max 30), evaluating the efficacy of a cleaning gel treatment of
truncal acne over a period of 84 days. In this study, the dermatologist could
adequately assess the improvement of truncal acne over time, since the same region
delineated by the individual mask was consistently investigated. This methodology
can be implemented in all clinical studies evaluating the efficacy of products for
truncal acne treatment.
Commercial Disclosure: Loan Towersey is a L’Oreal consultant paid to support the
study development.
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Nasosinusal mucosal melanoma
Mariano Marini, MD, Sanatorio G€
uemes; Luis Berrocal, MD, Sanatorio
G€
uemes; Carolina Galvis, MD, Sanatorio G€
uemes
A 73-year-old male, former tobacco smoker, with a personal history of cardiac
arrhythmias and hypertension and a first-degree relative with colorectal cancer,
consulted for 2 months of epistaxis associated with left nasal obstruction, proptosis,
epiphora and ipsilateral diplopia. Previous rhinoscopy showed a polypoid tumor,
occupying the left nostril and extending to the pyriform aperture, blackish and with
a visible vascular pattern that displaced the septum towards the right nostril. A
simple CT scan of the craniofacial mass showed lytic tumor lesions in the left nostril
with extension into the maxillary sinus, involving turbinates, nasal septum,
ethmoidal cells, orbital lamina and left frontal sinus. The diagnosis was complemented with histopathology, revealing nasal mucosal melanoma, ulcerated, without
presence of mitosis, lymphovascular or neural invasion. MRI and PET did not show
distant metastasis. The patient required multidisciplinary management and was
staged as T4aN0M0, clinical stage IVa (according to AJCC TNM classification) and
stage I (according to Ballantyne classification). Surgery was ruled out, indicating
management with radiotherapy and pembrolizumab 200 mg every 21 days in the
current follow-up, with partial improvement of nasal obstruction, without evidence
of clinical progression. The interest of this case lies in the infrequent and aggressive
presentation of melanoma of the nasal mucosa, being an oncologic entity of low
prevalence that corresponds to 1% of the total melanomas and less than 5% of the
neoplasias of the nasosinusal tract, having worse prognosis than cutaneous
melanoma due to its recurrence and high metastatic potential.
Commercial Disclosure: None identified.
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New onset scrotal lesions in a patient with herpes simplex virus
treated with foscarnet
Rebecca Wang, MD, Department of Dermatology, Henry Ford Hospital,
Detroit, MI; Ben J. Friedman, MD, Department of Dermatology, Henry
Ford Hospital, Detroit, MI
Introduction: Intravenous (IV) foscarnet is used for the treatment of acyclovirresistant herpes simplex virus (HSV). Foscarnet-induced penile ulcerations, thought
to be due to an irritant contact dermatitis, can occur where urine contacts the skin,
such as the glans penis adjacent to the urethral meatus. We present a gentleman who
developed serpiginous papules on the scrotum from foscarnet therapy.
Case Presentation: A 53-year-old African-American male with a history of HIV was
admitted to the hospital for IV foscarnet treatment of HSV of the penile shaft
recalcitrant to oral valacyclovir. Nine days after admission, the patient developed
new onset burning and painful lesions on the scrotum. On physical examination,
grouped serpiginous pink papules coalescing into a plaque on the left scrotum were
noted. HSV PCR was negative. Skin biopsy demonstrated an erosive dermatitis with
epidermal necrosis, supportive of an irritant contact dermatitis secondary to
foscarnet. Subsequently, the patient did endorse urine coming into contact with
his scrotum during urination. One week after stopping foscarnet, the scrotal lesions
subsided without further treatment.
Discussion: Penile ulcerations are a known but uncommonly encountered side
effect of foscarnet therapy. Nearly 90% of a foscarnet dose is excreted in the urine,
and it is thought that these ulcerations are due to an irritant contact dermatitis from
urine. Scrotal lesions presenting as serpiginous papules have less commonly been
reported. Foscarnet-induced irritant contact dermatitis should be considered in any
patient on foscarnet presenting with new onset lesions in the groin.
Commercial Disclosure: None identified.
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